Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827315 | 0.92 | CPB2 (0.70) | CPB2MMP3MMP8MMP14FOLH1 | |
| SCHEMBL6827305 | 0.80 | CPB2 (0.49) | CPB2MMP3FOLH1HTT | |
| SCHEMBL6827308 | 0.80 | CPB2 (0.49) | CPB2MMP3FOLH1HTT | |
| SCHEMBL14509143 | 0.78 | CPB2 (0.83) | CPB2MMP3HDAC3HDAC1HDAC2 | |
| SCHEMBL6827926 | 0.76 | CPB2 (0.98) | CPB2MMP3ANPEP | |
| SCHEMBL6827930 | 0.76 | CPB2 (0.98) | CPB2MMP3ANPEP | |
| SCHEMBL6824349 | 0.76 | CPB2 (0.98) | CPB2MMP3ANPEP | |
| SCHEMBL6824195 | 0.75 | CPB2 (1.00) | CPB2MMP3ANPEP | |
| SCHEMBL14542979 | 0.75 | CPB2 (1.00) | CPB2MMP3ANPEP | |
| SCHEMBL10737546 | 0.74 | HTT (0.51) | HSD17B10MMP3SIRT2SIRT1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | CPB2 8/4885HSD17B10 859/4885MMP3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.